Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Douglas, K.
Right arrow Articles by Bowman, S. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Douglas, K.
Right arrow Articles by Bowman, S. J.
Related Collections
Right arrow Health Economics
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 1416
© 2001 British Society for Rheumatology

Letters to the Editor

How many patients are eligible for anti-TNF therapy in the UK?

K. Douglas and S. J. Bowman

Rheumatology Department, Birmingham Heartlands & Solihull Hospitals NHS Trust, Bordesley Green East, Birmingham B9 5SS, UK.

SIR, Anti-tumour necrosis factor (TNF) therapies (infliximab and etanercept) are the first scientifically designed biological response modifiers to be licensed for use in rheumatoid arthritis (RA). Other novel therapies, such as interleukin 1 receptor antagonists, are in development. A British Society of Rheumatology (BSR) working party has prepared guidelines for the use of . . . [Full Text of this Article]

Notes


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
C. Deighton and K. Hyrich
Why do the French get much greater access to anti-TNF than the British? Vive la difference? Pas necessairement
Rheumatology, November 1, 2008; 47(11): 1600 - 1602.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
B. Fautrel, R. M. Flipo, and A. Saraux
Eligibility of rheumatoid arthritis patients for anti-TNF-{alpha} therapy according to the 2005 recommendations of the French and British Societies for Rheumatology
Rheumatology, November 1, 2008; 47(11): 1698 - 1703.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
R. Callaghan, A. Prabu, R. B. Allan, A. E. Clarke, N. Sutcliffe, Y. St. Pierre, C. Gordon, S. J. Bowman, and the UK Sjogren's Interest Group
Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome
Rheumatology, January 1, 2007; 46(1): 105 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
C.-S. Yee, A. Filer, A. Pace, K. Douglas, D. Situnayake, and I. F. Rowe
The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study
Rheumatology, July 1, 2003; 42(7): 856 - 859.
[Abstract] [Full Text] [PDF]